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The continuous search for antimicrobial candidates pushes the pursuit of compounds in the most 
diverse organisms. Amphibians are known as a prolific source of antibacterial peptides. Based on 
the rich biodiversity of the Amazon region the unexplored green-tree frog (Hypsiboas cinerascens) 
was studied for its skin secretion peptide content. Chromatographic separations and established 
tandem mass spectrometry (MS/MS) methods were used for sequencing the primary structures 
of the purified compounds. De novo sequencing lead to the identification of five new peptides 
related to hylaseptin P1, displaying an aminated C-terminal. Sequencing of the complementary 
deoxyribonucleic acid (cDNA) analysis allowed the disambiguation of isobaric amino-acids for 
C-01. Matrix assisted laser desorption ionization (MALDI) was carried out, demonstrating the 
in situ co-occurrence of the identified peptides in the dorsal skin. The major peptide C-01 was 
synthesized and assayed against a selection of microorganisms displaying minimal inhibitory 
concentrations (MICs) ranging from 4 to 16 µM.
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Introduction
Peptides are short chains of amino acids connected to 
one another in a sequence by peptide bonds.1 This type of 
compounds is widespread through all organisms such as 
plants, microorganisms and animals.2 In animals, peptides 
are involved in the complex coordination of the organism, 
mainly attributed to hormonal and neural activities.3 
Peptides also are involved in cell growth control that 
regulate not only cell proliferation but an extraordinary 
range of cell activities, including matrix protein deposition 
and resolution, the maintenance of cell viability, cell 
differentiation, inflammation, and tissue repair.4
Beyond these activities, a sub-class of peptides named 
antimicrobial peptides (AMPs) represents a promising 
source of active compounds to overcome increasing 
microbes strains resistant to some antibiotics.5 Most of 
these peptides are cationic and hydrophobic possessing 
the ability to permeabilize microorganisms membranes.6 
The amphipathic nature of AMPs allows the interaction 
with bacterial membranes through electrostatic bonds, 
resulting in a disruption process and consequently the cell 
death.7 This process can occur by more than one manner 
(detergent-like, barrel stave and pore toroidal mechanisms)8 
making it difficult for microorganisms to gain resistance 
to these peptides.9
Amphibians represent the main source of AMPs, these 
compounds are synthesized and stored in the granular 
glands of the dermal layer of the skin.10 AMPs and other 
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bioactive peptides are synthesized as larger proteins with 
a signal sequence and an acidic pro-piece that are cleaved 
to release the mature active peptide before or at the time of 
secretion from granular.6 The broad spectrum of pathogenic 
microorganisms that are inhibited by amphibian AMPs11 
attract attention for the discovery of new structures present 
in the skin secretions of these vertebrates.
Amphibians belonging to the Hylidae are known as a 
promising source of AMPs. Members of this family are 
commonly referred to as “tree-frogs” with adaptations 
suitable for an arboreal lifestyle, including forward-facing 
eyes providing binocular vision, and adhesive pads on 
the fingers and toes.12 In the non-arboreal species, these 
features may be greatly reduced, or absent.12 Several 
Hylidae genera have been reported as potent AMPs 
producers, such as Phyllomedusa, Hyla and Hypsiboas, 
all being found in the Amazon region.13 Hypsiboas is one 
of the less studied genera found in Brazil, where only 
H. puntacta had its peptide content previously evaluated.13 
The green-tree frog (H. cinerascens) is a nocturnal and 
arboreal species largely found in the rain forests of Central 
and South America14 not previously studied for its skin 
secretion’s peptide content.
The discovery of new amphibian AMPs requires the 
use of sensitive analytical techniques, since the amount of 
material is limited. In this case, mass spectrometry (MS) 
plays a central role when coupled to chromatographic 
techniques allowing the identification of several peptides 
in a single run, and with a restricted amount of material. 
Ambiguities such as the identification of isobaric residues 
(leucine and isoleucine) can be overcome by combination 
with molecular biology tools. Considering the increasing 
need for new antibiotics and the fact that the amphibians 
comprise a known source of biologically active molecules,11 
this work aimed for the identification of AMPs from the 
skin secretion of the tree frog H. cinerascens. An approach 
comprising high performance liquid chromatography 
(HPLC), MS and complementary deoxyribonucleic 
acid (cDNA) sequencing was applied enabling the 
identification of new AMPs named cinerascetins. 




Adult specimens of Hypsiboas cinerascens (n = 7) 
whose sex were not determinated were captured after 
acquisition of a license provided by the Instituto Brasileiro 
do Meio Ambiente e dos Recursos Naturais Renováveis 
(IBAMA, 22533-1) at Adolpho Ducke Reserve (Manaus, 
Amazonas State, Brazil) in the rainy season of 2010. All 
frogs were identified at the Department of Biology from 
the Federal University of Amazonas. Skin secretions were 
obtained by a gentle transdermal electrical stimulation 
of the dorsal skin (6 V)15 and collected in falcon tubes of 
15 mL after washing the cutaneous surface of the specimens 
with distilled water. Skin secretions of all specimens were 
combined, frozen and lyophilized yielding 1 mg of crude 
secretion. After collection, the specimens were released, 
with the exception of two, that were euthanized for cDNA 
sequencing and imaging analyses. The secretion was kept 
at 4 °C prior to being snap-frozen with liquid nitrogen, 
lyophilized and stored at –80 °C prior to analyses.
Chromatographic analysis and peptide isolation
The total lyophilized skin secretion was dissolved 
in 0.6 mL of water with 0.1% trifluoroacetic acid and 
injected into a reverse phase (C18) column (Vydac 218TP 
250 × 10 mm2, 5 µm particle size). The chromatographic 
system was a LC10 AD-VP (Shimadzu). Peptides were 
eluted out by performing a gradient of acetonitrile with 
0.1% trifluoroacetic acid ranging from 5 up to 95% over 
a period of 60 min under flow of 2.5 mL min-1. Peptide 
elution was monitored at 216 and 280 nm.16 All solvents 
used for chromatographic and MS techniques were HPLC 
grade purchased from J. T. Baker and the water was purified 
by a Milli-Q system.
Structural characterization
Chromatographic fractions were dissolved in 
10 µL of deionized water and mixed with α-cyano-4-
hydroxycinnamic acid matrix solution (5 mg of matrix, 
250 µL of deionized water, 50 µL acetonitrile with 0.1% 
trifluoroacetic acid) in a proportion of 1/3 µL followed 
by spotting matrix assisted laser desorption ionization 
(MALDI) target plate.16 For mass spectra acquisition, a 
MALDI-time-of-flight in tandem (MALDI-TOF-TOF) 
UltraFlex III mass spectrometer (Bruker Daltonics) was 
operated in the reflector mode for MALDI-TOF MS 
peptide mass fingerprint at a range of m/z 600-4000 and in 
the “LIFT™” mode for MALDI-TOF-TOF tandem mass 
spectrometry (MS/MS) fragmentation experiments, on fully 
manual mode using FlexControl software v. 2.2. To process 
the data obtained and perform manual de novo sequencing,17 
Flex Analysis v.3.0 software (Bruker Daltonics) was 
employed. The ambiguities on the fragmentation for 
peptides containing isobaric amino acids were approached 
by the molecular cloning of precursor-encoding cDNA.
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Sequence comparison
All obtained sequences were aligned and subjected 
to similarities search using the FASTA 3 program on the 
Expasy Molecular Server (www.expasy.ch) and online 
BLAST analysis (blastp) from the National Center for 
Biotechnology Information (NCBI). Secondary structure 
prediction was performed using SOPMA, also at this 
server.18
Molecular cloning of precursor-encoding cDNA
One specimen was euthanized by injection of a 2% 
lidocaine solution directly in the brain. Immediately, the skin 
was removed, frozen with liquid nitrogen and mechanically 
pulverized. The ribonucleic acid (RNA) isolation of 
approximately 10 mg of the skin was performed using 
trizol reagent (Invitrogen). Spectrophotometric analysis 
ensured the purity and quantity of RNA. The protocol for 
gene cloning and cDNA sequencing was carried according 
to Brand et al.19 Briefly, the total RNA (1 µg) was used for 
the first strand cDNA synthesis using a superscript reverse 
transcriptase kit (Invitrogen) and an oligo(dT)-anchor 
primer (5’-GACCACGCGTATCGATGTCGACTTTT 
TTTTTTTTTTTTT-3’).20 The cDNA amplification 
reactions employed the four degenerated 5’ primers 
PPS-1 (5’-ATGGCTTTCCTGAARAARTCBCTTTT 
Y C T T  G TA C TAT T C C T T G S - 3 ’ ) ,  P P S - 1 A 
( 5 ’ - AT G G C T T T C C T G A AG A A AT C T C T T T T 
C C T T G T A C T AT T C C T T G G - 3 ’ ) ,  P P S - 2 
( 5 ’ - AT G G C T T T C C T G A A R A A RT C B C T T T 
T Y C T T G TAT TAT T T C T C G G - 3 ’ )  a n d  P P S -
2A (5’-ATGGCTTTCCTGAAGAAATCTCTTTT 
CCTTGTATTATTTCTCGC-3’) that were designed based 
on the highly conserved 5’-signal regions of previously 
described AMPs cDNAs of anurans of the Hylidae family.21
Imaging analysis
The same euthanasia process was carried for other 
specimen, and immediately the whole dorsal skin was 
surgically removed. The dorsal skin was stretched over a 
glass plate and dried at room temperature. After dryness, 
the dorsal skin was fixed in a MALDI plate and covered 
with a thin layer of matrix solution (5 mg of α-cyano-4-
hydroxycinnamic acid, 250 µL of deionized water, 50 µL 
acetonitrile with 0.1% trifluoroacetic acid). The imaging 
analysis was performed on an Ultraflex III instrument on 
a reflective positive mode, with laser intensity at 30% 
and 200 µm of distance from each acquisition point. The 
data acquisition and post analysis was performed using 
Flex-imaging 3.0 software (Bruker Daltonics) which was 
programmed to map molecular components ranging from 
600 to 4000 m/z. The software Biomap was used to perform 
the ion co-localization analysis. The complete preparation 
of the dorsal frog skin fragment for MALDI imaging 
analysis has been described elsewhere.19
Solid phase peptide synthesis
The peptide C-01 was manually synthesized by the 
solid phase approach using the 9-fluorenylmethoxycarbonyl 
(Fmoc)/t-butyl chemistry according to the previously 
employed methodology.22 After chemical de-protection 
and lyophilization, the peptide was purified by reverse 
phase HPLC.
Antimicrobial assay
Candida albicans American Type Culture Collection 
(ATCC) 90028, Cryptococcus neoformans ATCC 28957, 
Escherichia coli ATCC 25922 and Staphylococcus aureus 
ATCC 25923 were used to evaluate the antimicrobial 
activity of C-01. Dermaseptin-1 (DS01) peptide, a known 
antimicrobial peptide isolated from frog skin, was used 
as positive control and pure water was used as negative 
control. The minimal inhibitory concentrations (MICs) were 
evaluated by broth microdilution test according to Clinical 
and Laboratory Standards Institute (CLSI) protocols.23 For 
yeasts, CLSI M27-A3 protocol was used. Briefly, yeast cell 
suspensions from 48 h old Sabouraud dextrose agar (SDA) 
were prepared in 0.85% (v/v) sodium chloride and diluted 
at appropriate densities in Roswell Park Memorial Institute 
(RPMI) 1640 broth (with L-glutamine, without bicarbonate, 
pH 7.0). A total of 1 × 103 cells were mixed at different 
peptides concentration ranging from 256 to 0.5 µM at a final 
volume of 100 µL. Experimental tests were incubated at 
35 ± 2 °C for 48 and 72 h for C. albicans and C. neoformans, 
respectively. MIC was determined as the concentration that 
no visible cell growth was observed after incubation period. 
All tests were performed in triplicate.
For bacteria, M07-A9 protocol was used.24 Prior to 
testing, bacteria were transferred to inclined casoy agar and 
incubated at 35 ± 2 °C for 24 h. Bacteria cells suspension 
were prepared in 0.85% (v/v) NaCl, diluted and adjusted to 
0.5 McFarland (1 × 108 colony-forming unit (CFU) mL-1).25 
Muller Hinton broth was used for antibacterial test. The 
final volume of 100 µL, containing different peptides 
concentration and 5 µL of bacteria inoculum were incubated 
at 35 ± 2 °C for 24 h. The MIC was determined as the 
concentration that no visible cell growth was observed after 
incubation period. All tests were performed in triplicate.26
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Results and Discussion
Peptide identification
The pooled skin secretion obtained from H. cinerascens 
was purified by reverse phase HPLC (Figure 1). Twenty 
fractions were manually collected and aliquots of each 
one containing the major peaks in the chromatogram 
were subjected to MALDI LIFT-TOF-MS/MS analysis. 
Chromatographic fractions eluting at 42.41, 34.90, 37.94, 
36.64 and 34.90 min (Figure 1) displayed ions whose 
monoisotopic masses were m/z 2386.43, 2395.25, 2165.30, 
2393.43 and 2490.50, respectively. MS/MS experiments 
allowed de novo sequencing of the major peaks. The manual 
interpretation of the product spectra displayed similar 
fragmentation behaviors, consistent with peptides sharing 
similar sequences named cinerascetins (C-01 to C-05). 
The chemical similarities among the isolated peptides 
demanded a carefully inspection of the fragmentation 
pattern.
The main peak observed at the chromatographic step 
(C-01) displayed the m/z 2386.4328 (–1.5 ppm) whose 
primary structure presented a sequence with 25 amino acid 
residues (GVI/LDAI/LKAI/LAKAAGKAAI/LQAAGEHI/
L-NH2). The monoisotopic mass of C-01 it showed to 
be 1 Da below the theoretical value (2387.3696). The 
observed m/z suggested a post-translational modification. 
Based on the sequencing and the recorded protonated 
peptide we proposed the existence of a carboxyamidated 
C-terminal residue. C-02 eluted at 34.90 min (m/z 2395.2525, 
+1.3 ppm) displaying a similar sequence to C-01, differing 
only at the residue number 18, where a histidine residue 
is found instead of a glutamine/lysine. The peptide C-03 
(m/z 2165.2939, 3.6 ppm) eluted at 37.94 min and its sequence 
is composed of 24 amino acid residues (GVSVI/LAI/LAGTI/
LAKAAGKAAI/LEAAI/L-NH2). The remaining peptides 
C-04 (m/z 2393.4300, –2.6 ppm) and C-05 (m/z 2490.5047, 
3.3 ppm) eluted in 36.64 and 34.50 min, respectively, 
containing 25 and 26 amino acid residues characterized as 
GVI/LDKI/LKAI/LAKAAGKAAI/LKAAGESI/L-NH2 and 
GVVI/LDKI/LKAI/LAKAAGKAAI/LQAAGEVV-NH2. 
For C-02 to C-05 the same 1 Da shifts on the recorded 
masses were observed, indicating that all identified 
peptides include a carboxyamidated C-terminal residue. 
AMPs with such modifications are largely found in 
Anuran. For the studied genus, H. pulchellus displayed 
peptides with the same post-translational modification.27 
Disambiguation of isobaric residues and confirmation of 
the post-translational modifications were carried by the 
cDNA analysis.
Figure 1. Chromatographic profile of the total skin secretion obtained from H. cinerascens. The fractions containing cinerascetins-01 to 05 (C-01 to C-05) 
were collected at 42.41, 34.90, 37.94, 36.64 and 34.50 min, respectively. The absorbance was monitored at 216 and 280 nm ((b) and (a) lines, respectively).
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Cloning of cinerascetins biosynthetic precursor-encoding 
cDNAs
In order to establish the isobaric residues such as 
leucine and isoleucine and residues with near masses 
(glutamine/lysine) the biosynthetic precursors were 
cloned. Four different cinerascetin-encoding sequences 
were consistently cloned from the skin secretion cDNA 
library. Unfortunately, from the MS-based identification 
only C-01 was encoded (Figure 2), whereas the remaining 
ones represent peptides not identified by MS. Those 
peptide sequences were named C-06, C-07 and C-08, 
since they displayed similar sequences when compared 
with the MS-identified ones. The ambiguities were 
resolved for C-01, where the obtained sequence was 
GVLDAIKAIAKAAGKAALQAAGEHI-NH2. All 
encoded peptides displayed a glycine at the end of the 
mature peptide followed by a stop codon, which is a 
confirmation of C-terminal amination during the peptide 
cleavage. NCBI-BLAST comparisons were performed 
with these four encoded peptides revealing that they 
possess novel sequences with high identities to known 
AMPs from Hypsiboas punctatus: 93% of identity with 
hylapseptin-P1;28 Phyllomedusa distincta: 65% with 
dermadistinctin-K;29 and Phyllomedusa sauvagii: 71% 
with dermaseptin-S5.30 On the other hand, cinerascetins 
displayed different sequences when compared with peptides 
reported from H. semilineatus,31 H. albopunctatus,32 
H. biobeba,33 H. raniceps,21 and H. pulchellus27 
(Table 1).
Imaging analysis
Imaging of biological tissues enables the molecular 
mapping of ions under almost native conditions, preserving 
morphological and molecular informations. Aiming to 
map the cinerascetins on the skin tissue and to compare 
their distribution on the skin, the total dorsal tissue of 
H. cinerascens was submitted to imaging acquisition. To 
facilitate observation of results, a representative fragment 
of analyzed skin is demonstrated in Figure 3. Pictorial 
representation of C-01 (m/z 2386.43), C-02 (m/z 2395.25), 
C-03 (m/z 2165.29), C-04 (m/z 2393.43) and C-05 
(m/z 2490.50) are shown in Figures 3c to 3g, respectively. 
Co-localization between C-01 (green) and the other related 
peptides (red) are shown in Figures 3h to 3k, respectively. 
The areas shared between two ions are shown in yellow. 
The technique was able to detect all reported cinerascetins 
in this work. The results indicate that C-01 is present in 
a great area of the dorsal tissue and that the other related 
peptides shared the same area. Thus, based on the primary 
structure and spatial location, the peptides C-02, C-03, C-04 
and C-05 probably have similar biological role as C-01.
Table 1. General characteristic of antimicrobial peptides derived from Hypsiboas species
Organism Peptide Sequence No.b Massc
H. cinerascens cinerascetin-01 GVLDAIKAIAKAAGKAAIQAAGEHI-NH2 25 2386.43
H. semilineatus Hs-1 FLPLILPSIVTALSSFLKQG 20 2144.60
H. albopunctatus hylin-1a IFGAILPLALGALKNLIK 18 1864.37
Ctx-Ha GWLDVAKKIGKAAFNVAKNFL/I 21 2289.73
H. biobeba hylin-b1 FIGAILPAIAGLVHGLINR 19 1945.36
H. punctata hylaseptin-P1 GILDAIKAIAKAAG 14 1311.80
phenylseptin FFFDTLKNLAGKVIGALT-NH2 18 1954.20
H. raniceps Rsp-1a AWLDKLKSLGKVVGKVALGVAQNYLNPQQ 29 –
H. pulchellus P1-Hp-1971 TKPTLLGLPLGAGPAAGPGKR-NH2 21 1971.35
aDetermined only by cDNA analysis; bNo.: number of residues; cmonoisotopic protonated peptide [M + H]+; dstructure confirmed by cDNA sequencing.
Figure 2. Nucleotide and translated amino acid sequences of cloned skin 
secretion-derived cDNA encoding the biosynthetic precursor of C-01. The 
signal peptide is shown double-underlined, mature peptide in single-line 
underline and stop codon is indicated with asterisk. Glycine amino acid 
residue indicates a possible amination.
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Solid phase synthesis and antimicrobial assay
Based on the structure of peptides characterized here 
and knowledge about the amphibian peptides antimicrobial 
potential, C-01 was selected to be manually synthesized for 
its antimicrobial evaluation. The peptide was prepared on a 
solid phase system and the purified peptide assayed against 
the yeast Cryptococcus neoformans, the fungus Candida 
albicans, the gram-positive bacteria Staphylococcus 
aureus and the gram-negative bacteria Escherichia coli, 
all human pathogens.34 The synthetic peptide was also 
evaluated against Xanthomonas axonopodis pv. glycines, 
a plant pathogenic bacteria. The peptide dermaseptin-01 
(DS01) obtained from Phyllomedusa hypochondrialis 
was used as positive control due to its antimicrobial 
properties.15
The peptide C-01 was able to inhibit the growth of 
all tested microorganisms with MIC values ranging from 
4 to 16 µM (Table 2). The uncommon broad spectrum 
activity of C-01 was shown to be more active than peptides 
previously described in Hypsiboas such as Rsp-1 (MIC 
of 20 µM against S. aureus)21 and hylaseptin-P1 (MIC of 
24.2 µM against E. coli).28 Over the last years a wide range 
of antimicrobial cationic peptides have been shown to play 
a significant role in host defenses.35 The mode of action 
of these peptides against gram-positive bacteria is well 
known,36 where the ability to form channels in lipid bilayer 
membranes seems to be most accepted theory.35 On the 
other hand the mechanism against gram-negative bacteria 
and fungi still remains unclear.36 The cationic nature of 
C-01 must be taken into account to determine the possible 
mechanism (76% of α-helix according to self-optimized 
prediction method with alignment (SOPMA) prediction). 
Similar anuran peptides such as dermaseptin-01 are also 
cationic, and it has been suggested that the membrane 
surface in the presence of negatively charged lipids is 
associated with a “carpet-like” manner, breaking the lipid 
bonds due the reduction of repulsive electrostatic forces 
between positively charged peptides.37 The similarities 
among dermaseptin-01 and C-01 may be the key to 
establish the mechanism of action, however, more studies 
to confirm this hypothesis are needed. Additionally, the 
presence of a carboxyamidated C-terminal moiety has 
been shown as a factor of increasing the antimicrobial 
activity, possibly by a decrease of degradation rate by 
carboxypeptidases.38
Conclusions
Using chromatography and MS it was possible 
to identify and characterize five new peptides. These 
compounds displayed sequences with 24 to 26 amino acid 
residues. Molecular cloning of precursor-encoding cDNA 
was performed and four sequences were identified, being 
one previously detected by MS. Imaging analysis with the 
dorsal skin allowed the localization of the MS identified 
peptides throughout the whole tissue. These peptides were 
assigned as new peptides related to hylaseptin-P1, displayed 
the C-terminal region with amination as post translational 
modifications. The synthetic peptide C-01 displayed in vitro 
antimicrobial activity against the tested organisms. The 
presented results are part of the continuous search for novel 
substances that can serve as models for new antibiotics. This 
work constitutes the first report on the peptide constitution 
of H. cinerascens.




C. albicans 10.00 7.64 n.d.e
C. neoformans 16.00 8.00 n.d.e
E. coli 16.00 1.00 n.d.e
S. aureus 10.00 8.00 n.d.e
X. axonopodis pv. glycines < 4.00 n.d.e n.d.e
aMIC (µM): minimal peptide concentrations required for total inhibition 
of cell growth in liquid medium; bC-01: synthetic peptide; cDS01: positive 
control; dwater: negative control; en.d.: not detected.
Figure 3. Imaging analysis of H. cinerascens skin. (a) Adult specimen 
of H. cinerascens; (b) analysis of the skin fragment; (c)-(g) pictorial 
representation of C-01 to C-05; (h)-(k) colocalization between C-01 and 
the other peptides; (l) global spectrum of detected ions.
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Supplementary Information
Supplementary data (imaging and MALDI LIFT-TOF-
MS/MS spectra of C-01, C-02, C-03, C-04 and C-05 and 
sequences of cDNA of C-06, C-07 and C-08) are available 
free of charge at http://jbcs.sbq.org.br as PDF file.
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